Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

In 2023, the FDA approved the Miebo (perfluorohexyloctane ophthalmic solution), an eyedrop that helps prevent tear evaporation. Also available in 2024 is a treatment known as Lacrifill. It is injected ...

The debt refinancing is expected to help the company in the impending spinoff of its eye-care company, Bausch + Lomb. This drugmaker is expected to post quarterly earnings of $1.05 per share in ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is exploring a potential sale and is seeing interest from private equity ...

Bausch & Lomb (NYSE:BLCO) rose 9% after a report about private equity interest in a takeover of the eyecare company. Private equity firms including Blackstone (BX), Advent International ...

Separate from the refinancing option, Bausch + Lomb is exploring a sale of itself, which could draw interest from private equity buyers. Wed, 18 Sep, 2024 - 10:13 Bausch Health is working with ...

Bausch + Lomb was put up for sale after a planned separation ... from sales of contact lenses and dry eye drugs Xiidra and Miebo. The company also sells surgical equipment to ophthalmologists.

(Bloomberg) -- Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb, ...

(Bloomberg) -- Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb ...